

FORM 7

**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: Cannvas MedTech Inc. (the "Issuer" or "Cannvas").

Trading Symbol: MTEC

Number of Outstanding Listed Securities: 43,314,461

Date: October 3, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**See Item 2 below for a complete overview and discussion of the Issuer's activities for the month of September 2018.**

- 2. Provide a general overview and discussion of the activities of management.

**On September 4, 2018, the Issuer announced its vendor of choice for integration to its Artificial Intelligence (A.I) component powering the Cannvas.me cannabis education platform.**

**IBM Watson has been chosen to power the A.I. analytics branch of the Cannvas platform. It will serve as a best-in-class integrated solution most relevant and attuned for the persona-driven architecture of the platform. Leveraging IBMs A.I. service allows the Cannvas team to quickly analyze through the copious amounts of data attributes comprising the Cannvas.me platform in a relevant and real-time fashion for its user base.**

**Deriving industry and customer insights in a real-time fashion for the CRM program requires the use of technologies that are at the leading edge of their space. Utilizing IBM Watsons capabilities allows the Cannvas technology stack to achieve this goal. Cannvas.me takes the traditional Email Customer Journey and transforms it into a true Omni-Channel approach where user preferences and insights are utilized to serve a fully personalized message experience through the channel of their choice. Cannvas.me will be able to truly embrace the concept of Omni-Channel marketing.**

Having a data technology solution that is recognized as a leader in its space allows the Cannabis team to utilize years of A.I. advancements that the IBM team has been pushing forth within the field.

On September 6, 2018, the Issuer announced that has established an industry framework for data reporting and analytics for the Canadian and global cannabis marketplace. Data and information captured through Cannabis.me, a global cannabis education platform, will be presented through a self-serve delivery system with innovative forms of information filtering and processing for enhanced insight and decision making.

Data is a major priority for corporations of all sizes. By using advanced technology, machine learning algorithms and artificial intelligence, Cannabis Data will analyze the large data sets captured from Cannabis.me online platform. The data originating from Cannabis.me, clinical and academic research, government reports and other sources will contain a broad spectrum of data points types, that when analyzed will uncover market trend, hidden patterns, unknown correlations, customer preferences and other valuable business information.

### About Cannabis Data

Cannabis Data is pioneering to be the census data of the cannabis industry by leveraging advanced technology, machine learning algorithms and scientific and medical research data to provide meaningful insights to the global cannabis community. Operating as part of the Cannabis.me platform, Cannabis Data analyzes a multitude of data points captured from those using medical and recreational cannabis to improve their health and wellness. The platform is LP/REC agnostic which means it is not biased by the personal drivers of any one company or institution, and it is continuously evolving and adapting to users and recognizing and learning from changing trends. For more information visit: [www.cannvasdata.com](http://www.cannvasdata.com)

On September 10, 2018, the Issuer announced that it is developing an online data and analytics portal whereby stakeholders will have the ability to gain access, explore and learn about actionable insights regarding the Canadian and global cannabis marketplace. The online data and analytics portal will feature an intuitive smart dashboard specifically designed for segments of the market with features to quickly access, process and visualize data.

The Cannabis.Me cannabis education platform was built using contextual technology and incorporates artificial intelligence, whereby user preferences and insights are utilized to serve a fully personalized message experience through the channel of choice. As customers navigate through each individual experience, data is captured at every step of the way. Data originating from clinical and academic research, government reports and other sources are also captured by the system and included in the database.

Cannabis Data controls the data aggregation, reporting framework and online data and analytic tools to quickly manipulate vast amounts of data within an easy-to-use intuitive smart dashboard environment, to uncover market trends, hidden patterns, unknown correlations, customer preferences and other valuable business information.

On September 11, 2018, the Issuer announced that it has entered into a letter of intent (the "LOI"), to negotiate, in good faith, a data analytics agreement with respect to "CannaBLOX", a Blockchain-based smart contract supply chain management platform for the legalized Cannabis industry that BLOX is developing in partnership with Liberty Leaf Holdings Ltd. (CSE: LIB) (OTC: LIBFF) (FSE: HN3P).

Under the terms of the Agreement, the Parties will assess, amongst other endeavors, various synergies that may exist through the utilization of Cannabis Data's analytical modeling framework and the various data capture opportunities that the CannaBLOX platform would provide. Cannabis will develop specific parameters within its existing Cannabis Data framework to collect and analyze transactional and industry data from the CannaBLOX platform, and their strategic industry partners. CannaBLOX would in turn gain access to a broad industry-level dataset as they rollout their preliminary module during a beta test phase.

Analytics from CannaBLOX will provide Cannabis Data with the additional insights of supply chain management, dissemination of cannabis products and their volumes within Canada, and various other transactional information from its seed-to-sale solution. Our mission statement for Cannabis Data is to collect and analyze data from various credible sources to enhance our ongoing analytical and modeling framework for the cannabis industry. Cannabis Data will continue to leverage existing partnership databases, site traffic and contextual technology for user engagement purposes to further its analytical solutions for the global cannabis community. The Parties have agreed to a discovery period whereby the technological specifications of the integration will be setup by Cannabis Data and will work together towards a definitive partnership agreement within the next 60 days.

#### **About Blox Labs**

Blox Labs Inc. is a technology development company focused on creating best-in-class software solutions driven by emerging trends in Blockchain, Smart Contracts and Decentralized Applications. BLOX is helping customers with solutions for business problems from proofs of concept through execution. The Company is currently piloting blockchain solutions for supply chain management and improvement as well as other areas. BLOX is actively targeting partnerships and strategic acquisitions of growth companies.

On September 13, 2018, the Issuer announced that it will introduce its second cannabis-centric educational platform, aimed at healthcare and wellness through cannabis for furry family friends. Built on the same infrastructure as Cannabis.Me, Cannabis.PET will be a scalable and comprehensive solution for the global pet community offering interactive tools and research-backed content to audiences who wish to learn about pet healthcare through cannabis.

Similar to the Cannabis.Me education platform, Cannabis.PET will be a free-to-use online platform using machine-learning algorithms and artificial intelligence to contextualize and adapt to users of the platform, ensuring the content they are served remains geographically and personally relevant to them. The site will feature innovative tools such as educational learning modules and an interactive service to educate pet owners with specific concerns about the different strains available.

With the legalization of cannabis on October 17, 2018 Canadian pet owners will have the opportunity to use medical-grade cannabis for the health care of their pets. Similar to the human medical cannabis marketplace, high-quality non-combustible cannabis products can be a natural alternative in supporting the overall health and well-being of pets. Pets suffer just like humans and with the growing demand for alternative treatments there is a need for a trusted source of medical cannabis treatments to help with pet-related ailments. Research on CBD treats and oils has shown promise in many pet ailments like phobias, digestive problems inflammation and pain.

In Canada, there are approximately 16 million cats and dogs with almost two-thirds of households owning a pet. Pet owners are increasingly treating pets as an extension of their family, driving annual pet-related expenditures to in excess of \$5 billion in Canada and almost US\$70 billion in the United States.

With over 350 million pets globally, there is a sizeable market opportunity for cannabis products and supporting technologies like the scalable Cannabis.PET educational platform.

On September 18, 2018, the Issuer announced that it is continuing to develop a substantial set of educational modules surrounding the consumption of cannabis-infused food and beverages for its Cannabis.Me educational platform. Leveraging the Company's Health and Innovation Advisory Board, Medical Advisory Board and Education Advisory Panel, made up of members from industry and government institutions, Cannabis.Me will deliver comprehensive and credible information on the potential benefits of cannabis-infused edibles.

As the Issuer continues to grow, recently expanding its team to 19 members and actively growing its partnership base with national and international organizations, it intends to harness the expertise of its staff, who bring with them years of experience working with food and beverage clients across Canada, to further guide content creation centered around cannabis-infused food and beverage.

Cannvas recently hired Daniel Davidzon, who brings with him a wealth of experience in the foodservice industry including having helped grow Aroma Espresso Bar Canada from 20 to 46 locations in a four-year span.

On September 24, 2018, the Issuer announced that it has entered into a of an LOI with Advica Health, an innovative patient-navigation membership service, to negotiate, in good faith, an agreement whereby Cannvas will become the exclusive provider of cannabis information and education to the Advica Health membership.

Advica Health offers members access to the best facilities at home or abroad and assists to obtain advice, treatment options and solutions to current health care situations in the most efficient manner possible. Each case is approached on an individualized basis, to help navigate the current healthcare system and collaboratively create an effective health plan with ongoing care management and support from nurse navigators. Advica is constantly bringing innovative healthcare solutions to its membership, with a strong focus on preventative health and wellness. By keeping health top-of-mind, Advica helps members focus on healthy living, which highly impacts overall productivity and quality of life.

Through widespread integration, medical professionals and patients will be able to access the Cannvas.Me education platform when and where necessary. With membership-based programs such as Advica Health, patients can be referred to the online portal. For patients visiting participating medical clinics or related facilities, Cannvas offers a low-cost, application-specific handheld device that provides access to the benefits of health and wellness through cannabis and information specific to their needs.

Access to trusted information is important for both the patient and the prescribing medical professional. Due to the lack of available information, medical professionals have been reluctant to prescribe cannabis in its many forms. Providing information at the source of treatment gives patients peace of mind by exploring all alternatives, and doctors confidence to write suitable prescriptions for specific ailments.

#### **About Advica Health**

Advica is dedicated to support Canadians who want to personalize their individual medical treatment. Advica acts as thoughtful advisors to assist patients to improve health and wellness.

On September 26, 2018, the Issuer announced that Cannvas.Me, its first cannabis-centric service offering to the public, will go live on October 4, 2018. Cannvas.Me is a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content to all audiences wishing to learn about health care through cannabis.

Cannvas has been systematic in its approach to the development of the innovative platform, ensuring a best-in-class experience for all users. The free platform utilizes machine-learning algorithms and artificial intelligence (AI) to contextualize and adapt to its users. Content will be served in a geographic and personal manner relevant to the customer. The contextual AI-supported service also ensures each customer's journey is built upon their last interaction, giving individuals a uniquely progressive experience.

Cannvas.Me features an innovative set of tools making cannabis education approachable and accessible to a global audience, including:

- educational learning modules created by medical practitioners and certified educators as part of its Cannvas Academy;
- an interactive Cannvas Strain Matcher teaching users which strains best alleviate specific ailments;
- curated recipes and culinary cannabis training with Cannvas Culinary;
- and more.

The physician-backed information presented on the site is vetted through a series of systems and reviews to ensure the most accurate and up-to-date information is available. Cannabis has formed three advisory boards and panels with seasoned medical and educational professionals who are at the forefront of their respective fields:

- Health and Innovation Advisory Board
- Medical Advisory Board
- Education Advisory Panel

The members of the advisory boards work with the senior executive team to create original content for the platform offering users relevant and credible information in a rich and contextual environment.

On September 27, 2018, the Issuer announced the formation of Cannabis Cannabis Acquisitions Corp., a wholly-owned subsidiary with a focus on investment and acquisition in the expanding global cannabis sector.

Cannabis Cannabis Acquisitions seeks to complement Cannabis' current product offering through continuous development, strategic investments and acquisitions in the cannabis sector. Related companies may include, but are not limited to:

- Technology
- Marketing and design
- Packaging
- Food and nutraceuticals
- Regulation and enforcement
- New product development
- Cultivation related equipment
- Gear and paraphernalia
- Retail stores & dispensaries
- Testing labs

Cannabis research sources calculate legal pot sales in North America climbed approximately 33% in 2017 to almost \$10 billion, and project annual sales will grow to \$25 billion by 2021. In a 2017 study, Deloitte estimates the size of the ancillary cannabis market to be approximately 2.5 times the size of the actual cannabis cultivation market.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**See Item 2 above. Blox Labs and Advica Health are not Related Parties of the Issuer.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.  
**N/A.**
8. Describe the acquisition of new customers or loss of customers.  
**N/A.**
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.  
**None.**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.  
**None.**
11. Report on any labour disputes and resolutions of those disputes if applicable.  
**None.**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  
**None.**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  
**N/A.**
14. Provide details of any securities issued and options or warrants granted.  
**None.**
15. Provide details of any loans to or by Related Persons.  
**N/A.**
16. Provide details of any changes in directors, officers or committee members.  
**None,**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.  
**Changes in commodity prices, in particular metal prices, and changes in the share performance of other junior mineral exploration companies may affect the Issuer's ability to raise financing.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **October 3, 2018** \_\_\_\_\_.

Shawn Moniz  
Name of Director or Senior Officer

"Shawn Moniz"  
Signature

CEO & Director  
Official Capacity

|   |  |  |
|---|--|--|
| <b><i>Issuer Details</i></b><br>Name of Issuer  | For Month End  | Date of Report<br>YY/MM/D                    |
| <b>Canvas MedTech Inc.</b>  | <b>September 2018</b>  | <b>18/10/03</b>                              |
| Issuer Address<br><b>201-213 Sterling Road</b>  |  |  |
| City/Province/Postal Code<br><b>Toronto, ON M6R 2B2</b>                                       | Issuer Fax No.<br><b>N/A</b>   | Issuer Telephone No.<br><b>800.489.0116</b>  |
| Contact Name<br><b>Shawn Moniz</b>  | Contact Position<br><b>CEO &amp; Director</b>  | Contact Telephone No.<br><b>800.489.0116</b> |
| Contact Email Address<br><a href="mailto:info@cannvasmedtech.com">info@cannvasmedtech.com</a> | Web Site Address<br><a href="http://www.cannvasmedtech.com">www.cannvasmedtech.com</a> |  |